IMPORTANCE Racial differences in molecular biomarkers for Alzheimer disease may suggest race-dependent biological mechanisms.
P otential racial differences have been examined in Alzheimer disease (AD), particularly for African American individuals compared with non-Hispanic white individuals, 1 but the evidence is often conflicting. For example, some studies suggest an increased incidence and prevalence for dementia and AD in African American individuals compared with non-Hispanic white individuals, 2-4 but other studies find no racial differences in the risk for AD. 5, 6 There are similar discrepancies as to whether AD-related neuropathologic differences do 7 or do not 8, 9 exist between African American and white individuals and whether there are racial differences in hippocampal volumes.
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The mixed results regarding the risk for and expression of AD in African American vs white individuals may be associated, at least in part, with whether there was adjustment for factors that may affect expression of disease. Socioeconomic disparities (including in educational quality) 12 ; psychosocial factors (including the stress of lifelong discrimination) 13 ; and comorbid diseases such as cardiovascular disease and its risk factors, 14 all may interact to influence racial differences in AD. 15 Finally, although African American individuals represent 13.3% of the population in the United States, 16 they are often underrepresented in AD clinical cohorts such that AD research largely has been informed by white research volunteers. For example, only 33 of 2129 participants (1.6%) in a phase 3 trial of solanezumab were African American. 17 Furthermore, as of August 2018, the database representing participants from all Alzheimer's Disease Centers, as maintained by the National Alzheimer's Coordinating Center, 18 had neuropathologic data from 5283 brains, of which only 321 (6.1%) were from African American individuals; the autopsy rate for African American individuals entered into the National Alzheimer's Coordinating Center database is 25.3% compared with 62.1% for white individuals. Molecular biomarkers for AD refer to the misaggregated proteins amyloid-β42 (Aβ42) and tau as identified by positron emission tomography (PET) of the brain with radioligands for amyloid plaques and for tau deposition or by the concentrations of these proteins in cerebrospinal fluid (CSF). Biological markers of AD permit the in vivo study of Alzheimer pathophysiologic characteristics in humans. Few studies, however, have compared molecular biomarkers of AD in African American and white individuals to determine whether or not there are potential disparities in underlying AD mechanisms. [19] [20] [21] There also could be important practical considerations should there be racial differences in AD biomarkers. For example, differences would require race-dependent thresholds for biomarker positivity to be used in AD research studies, including screening for clinical trials of experimental therapies. 22 We thus reviewed molecular biomarker results in 
CSF Collection and Analysis
Participants underwent LP at 8 AM after overnight fasting; typically, 20 to 30 mL of CSF was collected under gravity flow. The CSF was gently inverted to disrupt potential gradient effects, centrifuged at low speed to pellet any cellular debris, aliquoted into polypropylene tubes, and stored at -80°C as previously described. 
MRI Acquisition and Processing
Structural, magnetization-prepared, rapid gradient-echo images were collected using either a 1.5-T or 3-T Siemens scanner. Scans had a resolution of either 1×1×1.25mmor1×1×1 mm. Scans were processed with Freesurfer 29 to parcellate the cortex using the Desikan atlas. 30 For each hemisphere, volumes were obtained for all subcortical regions. The volumes of subcortical structures were adjusted for differences in intracranial volume using a regression approach. 31 Current analyses focus on the volume of the hippocampus, as this region has previously been shown to be affected in AD.
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PET Acquisition and Processing
Amyloid-β PET imaging was completed using carbon 11-labeled [ 11 C] Pittsburgh compound B (PiB). 34 Positron emission tomographic data from the 30-to 60-minute postinjection window were analyzed using FreeSurfer regions of interest. 35 Regional values were transformed into standardized uptake value ratios (SUVRs) using the cerebellar cortex as the reference region. Data were partial-volume corrected using a regional spread function. 36 Regions known to be sensitive to AD pathologic characteristics were averaged together to represent global amyloid-β burden. 35 
Sequencing and Genotyping
Apolipoprotein E genotype was determined for all individuals. Briefly, APOE ε2,ε3, and ε4 isoforms were determined by genotyping rs7412 and rs429358 using Taqman genotyping technology as previously described. 37 
Ascertainment of Cerebral Ischemic Lesions
Research brain MRI scans were reviewed by a neuroradiologist to ascertain incidental findings that may be clinically actionable. These findings include ischemic lesions, such as lacunes and infarcts. The number of neuroradiological reports of such ischemic lesions was noted for both African American and white participants.
Statistical Analysis
Statistical analysis was conducted from April 22, 2016, to August 27, 2018. The analysis sample included all individuals from Knight ADRC who had cross-sectional data for at least 1 biomarker modality (amyloid-β PET, CSF, and/or brain MRI) from January 1, 2004, through December 31, 2015. There were too few completed longitudinal biomarker procedures to date in African American individuals to permit analysis. Independent cross-sectional analyses were conducted for each modality because some individuals chose to participate in some biomarker studies but not the others. Analysis of variance or analysis of covariance, as appropriate, was used to assess the association between biomarker values (CSF and imaging) and race (African American vs white) jointly with other covariates including sex, APOE ε4 status, age, educational level, clinical status (CDR of 0 vs CDR >0), family history of AD, and BMI (eTables 1-3 in the Supplement provide the unadjusted values). The presence of ischemic lesions on MRI findings and HbA 1c values were initially considered as covariates in the adjusted analyses, but because of the fact that the initial adjusted analyses indicated no significant effects of these covariates on any of the biomarkers under analysis, they were not included in the final adjusted analyses. All analyses first examined the interactive effect between race and each of the other covariates. If the interaction was significant, the differential race effect on the biomarkers was reported depending on the level of the other covariate. If the interaction was not significant, the race effect on the biomarkers was reported as the main effect regardless of the levels of the other covari-ates. Because values of some CSF biomarkers as measured by the INNOTEST assay have drifted over time, 38 we adjusted for the effect of assay drift by including assay date and type as covariates in all analyses of CSF biomarkers. All analyses were done by SAS PROC/GLM, version 9.4 (SAS Institute Inc). All P values were from 2-sided tests, and results were deemed statistically significant at P < .05.
Results
Clinical
The characteristics of the sample at the clinical assessment closest in time to the participant's biomarker acquisition are shown in ); no racial differences were noted for individuals without a family history of dementia. The adjusted analyses revealed that the 2 races shared effects of age and of CDR for smaller mean (SE) total hippocampal volumes. In the combined sample, increased age was associated with smaller total mean (SE) hippocampal volume (-59 ; P < .001). There was no effect of severity of dementia (ie, CDR of 0.5 vs CDR of ≥1) on hippocampal volume.
Amyloid PET
No racial difference was observed on partial volumecorrected mean cortical PiB SUVR. However, in the combined Table 3) . When the amyloid-β PET data were converted to the Centiloid scale as previously described, 39 the results were consistent with those reported as SUVRs (Table 3) .
CSF Concentrations
There was no difference between African American and white participants for CSF concentrations of Aβ42 ( Table 4) . In the combined sample, there was an APOE ε4 effect, as APOE ε4 carriers had lower mean (SE) CSF Aβ42 concentra- Table 4 ). Further adjustments of other covariates (APOE ε4 status, sex, educational level, CDR, BMI, and family history of AD, in addition to age and race) on CSF t-tau confirmed these racial differences and an additional CDR effect (those with a CDR >0 had higher t-tau levels). Further adjustments of these same covariates on CSF t-tau and p-tau 181 also revealed a race by APOE ε4 interaction. Among individuals carrying an APOE ε4 allele, mean (SE) concentrations of both CSF t-tau and p-tau 181 
Discussion
Compared with white individuals, we found that African American individuals (1) have reduced CSF levels of t-tau and p-tau 181 , perhaps as a function of the presence of APOE ε4; (2) have lower hippocampal volumes for those reporting a family history of dementia; (3) have equivalent amyloid-β burden as determined by global PiB SUVRs and CSF Aβ42 concentrations; and (4) share an identical AD biosignature, such that amyloid burden and CSF t-tau and p-tau 181 concentrations increase as a function of age and clinical status (CDR >0). Moreover, the presence of an APOE ε4 allele is associated with increased amyloid PET SUVR and with decreased CSF Aβ42 levels in both African American and white individuals.
Our findings that, compared with white individuals, African American individuals have lower levels of CSF t-tau and p-tau 181 is consistent with results from a study of 65 African American individuals and 70 white individuals as recently reported by Howell and colleagues. 21 We found that the lower levels of CSF t-tau and p-tau 181 for African American individuals was largely a function of carrying an APOE ε4 allele; African American noncarriers of an APOE ε4 allele did not have significantly different concentrations of CSF t-tau and p-tau 181 when compared with white individuals, although there was a trend for lower CSF t-tau in African American noncarriers. These findings suggest that the racial differences in CSF t-tau and p-tau 181 may, at least in part, reflect a differential effect of APOE ε4, perhaps similar to the lack of an APOE ε4 effect for the risk of cerebral hemorrhage in African American individuals compared with white individuals. 40 The lower absolute levels of CSF t-tau and p-tau 181 in African American individuals are not readily explained by the presence of comorbid cerebrovascular disease, at least as suggested by the proxy of ischemic lesions on MRI findings. Given recent evidence that APOE ε4 influences tau pathogenesis and tau-mediated neurodegeneration independent of Aβ pathologic characteristics, 41 it is possible that the interactions of APOE ε4 with tau in African American individuals differs from its interactions with tau in white individuals, perhaps similar to the observed weaker association in African American individuals of APOE ε4 with AD. Although our finding that African American individuals who were APOE ε4 carriers had higher PiB uptake on amyloid PET scans is consistent with the ARIC study, 19 in general, the association of APOE ε4 and AD in African American individuals is weaker for African American individuals than for white individuals. 42 Osuntokun and colleagues 44 found no correlation of APOE ε4 with the prevalence of AD in community-dwelling older Yoruba individuals in the city of Ibadan, Nigeria. Similarly, a population-based study in New York City found an increased frequency of AD in African 48 and COBL (OMIM 610317) and SLC10A2 (OMIM 601295). 49 In addition to the potential risk-modifying effects of these variants on environmental factors important for AD, it may be that 1 or more of these variants attenuates the effect of APOE ε4 such that African American individuals have less APOE ε4-associated risk for AD than do white individuals. 
Limitations
To our knowledge, our study is the first to examine racial differences in molecular biomarkers of AD in which the cohort contributed data for both amyloid concentrations as seen on PET scan and CSF concentrations of Aβ42, t-tau, and p-tau 181 . Caution is needed in interpreting our results until they can be confirmed (or refuted) with subsequent analyses in larger cohorts to carefully explore the influences of socioeconomic status, comorbid diseases, and other factors that may contribute to racial differences. Another limitation is that our examination was restricted to African American and white individuals. It will be important to study the expression of molecular biomarkers of AD across all racial and ethnic groups to identify factors that may differentially affect AD risk and expression. Individuals who agree to participate in AD biomarker studies are almost certainly not representative of the overall population; thus, these results may not be generalizable. Also, our assessment of socioeconomic status was limited to educational level, and our assessment of cerebrovascular disease was limited to ischemic lesions on the brain MRI findings; thus, we may have failed to capture other aspects of these important risk factors. Finally, this study is limited by its cross-sectional nature that precludes correlating the biomarker values with progression of AD.
Conclusions
Despite these limitations, this study indicates that racial differences are present in some biomarkers of AD, 
